Real‐World Effectiveness and Safety of Mepolizumab in Pediatric Severe Eosinophilic Asthma: A Multicenter Study
Pediatric Pulmonology · 2026-01 · 61 (1)
DOI: 10.1002/ppul.71466 ↗At a glance
Multizentrische Studie in Pediatric Pulmonology, published online on 2026-01-12. Written by Nadira Nabiyeva Çevik and 8 co-authors. Institution: Department of Pediatric Allergy, Hacettepe University, Faculty of Medicine, Ankara, Türkiye. Major MEDLINE topics: Antibodies, Monoclonal, Humanized, Asthma, Anti-Asthmatic Agents. Cited 1 times so far (Crossref); 26 references.
Abstract (original language)
Background
Severe asthma (SA) in children is a complex condition with high morbidity and healthcare costs. Mepolizumab, an anti‐interleukin‐5 biologic, is approved for severe eosinophilic asthma (SEA) in patients ≥ 6 years, yet long‐term real‐world pediatric data remain limited.
Aim
To assess the long‐term safety and effectiveness of mepolizumab in pediatric SEA, focusing on lung function, oral corticosteroid (OCS) use, and exacerbation rates.
Methods
This retrospective, multicenter study examined the medical records of 33 patients with SEA (aged 6–17 years) who received mepolizumab treatment at three tertiary centers in Turkiye. Inclusion criteria included GINA‐defined SA, ≥ 2 severe exacerbations in the previous year requiring OCS, high‐dose ICS plus a second controller, and elevated eosinophil counts. Data on exacerbations, pulmonary function tests (PFTs), OCS use, ACT scores, eosinophils, and adverse events were collected over 24 months.
Results
At baseline, patients showed poor asthma control (median ACT: 13), impaired lung function (FEV1%: 62%), and frequent exacerbations (median: 7/year). Mepolizumab significantly reduced exacerbation rates (median: 7 to 0–0.05 at 12/24 months, p = 0.005) and OCS use (87.9% OCS‐free by 3 months). ACT scores improved (median: 13–25, p < 0.001), as did FEV1% (62% to 89%, p < 0.001) at 24 months. Eosinophil counts decreased markedly (460 to 50 cells/µL, p < 0.001). The treatment was well‐tolerated; one patient discontinued due to anaphylaxis and four due to lack of efficacy.
Conclusion
Mepolizumab showed sustained effectiveness and good tolerability in pediatric SEA, significantly reducing exacerbations and OCS use while improving asthma control and lung function. These findings support its real‐world utility and underscore the need for careful patient selection and monitoring.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Pediatric Allergy, Hacettepe University, Faculty of Medicine, Ankara, Türkiye.
- Department of Pediatric Allergy and Immunology, Akdeniz University, Antalya, Türkiye.
- Department of Pediatric Allergy, Cukurova University, Faculty of Medicine, Adana, Türkiye.
ORCID profiles: Nadira Nabiyeva Çevik, Melike Ocak, Aysen Bingol, Bulent Enis Sekerel
Cite
APA
Çevik, N. N., Ocak, M., Kocatepe, G., Teker, N. B., Kocacik Uygun, D. F., Serbes, M., Ozcan, D., Bingol, A., & Sekerel, B. E. (2026). Real‐World Effectiveness and Safety of Mepolizumab in Pediatric Severe Eosinophilic Asthma: A Multicenter Study. Pediatric Pulmonology, 61(1). https://doi.org/10.1002/ppul.71466
Vancouver
Çevik NN, Ocak M, Kocatepe G, Teker NB, Kocacik Uygun DF, Serbes M, et al. Real‐World Effectiveness and Safety of Mepolizumab in Pediatric Severe Eosinophilic Asthma: A Multicenter Study. Pediatric Pulmonology. 2026;61(1). doi:10.1002/ppul.71466
BibTeX
@article{evik2026,
author = {Çevik, Nadira Nabiyeva and Ocak, Melike and Kocatepe, Gaye and Teker, Nilgün Bahar and Kocacik Uygun, Dilara Fatma and Serbes, Mahir and Ozcan, Dilek and Bingol, Aysen and Sekerel, Bulent Enis},
title = {Real‐World Effectiveness and Safety of Mepolizumab in Pediatric Severe Eosinophilic Asthma: A Multicenter Study},
journal = {Pediatric Pulmonology},
year = {2026},
volume = {61},
number = {1},
doi = {10.1002/ppul.71466}
}
EUVIMED